Welcome to our dedicated page for Ainos SEC filings (Ticker: AIMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Ainos’ dual play in low-dose interferon therapeutics and AI Nose diagnostics often means skimming hundreds of dense pages. Clinical trial data, VOC-sensor patents, and licensing details are scattered across 10-K risk factors, 10-Q footnotes, and 8-K partnership updates—information critical to anyone tracking this innovative biotech.
Stock Titan solves that problem. Our AI engine turns every new Ainos quarterly earnings report 10-Q filing into plain-English snapshots minutes after it hits EDGAR. Looking for Ainos insider trading Form 4 transactions or need Ainos Form 4 insider transactions real-time? You’ll get instant alerts and context. Want Ainos annual report 10-K simplified? We highlight R&D spend, FDA milestones, and AI Nose commercial timelines. Each document—whether an 8-K material events explained notice or the proxy statement executive compensation schedule—arrives with side-by-side figures, trend charts, and plain-language explanations.
The result: faster, smarter decisions. Compare spend across clinical programs, monitor Ainos executive stock transactions Form 4 before trial readouts, or dive into Ainos earnings report filing analysis without wading through accounting jargon. Our coverage spans every form: S-1 capital raises, Ainos proxy statement executive compensation disclosures, even niche submissions. With real-time feeds and understanding Ainos SEC documents with AI summaries, you’ll never miss a material update again.
Ainos, Inc. (AIMD) filed its Q3 2025 10‑Q, reporting continued operating losses with limited cash. Nine‑month revenue was $113,037, up from $20,729, driven mainly by VOC sensing co‑development and modest VELDONA Pet sales. Net loss was $10,302,714, and operating loss reached $9,692,751. Cash and cash equivalents were $1,128,217 at September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern.
To support liquidity, Ainos used its at‑the‑market program with H.C. Wainwright, selling 674,867 shares for $1,852,895 in net proceeds through September 30 and an additional 18,837 shares for $68,151 from October 1 to November 13. Shares outstanding were 4,793,797 as of September 30 and 4,812,634 as of November 13, 2025, following a 1‑for‑5 reverse split effective June 30. R&D expenses were $5,626,514 and SG&A $4,159,627 for the first nine months, reflecting ongoing investment in AI Nose, POCT, and VELDONA development while the business advances pilot deployments and partnerships.
Ainos, Inc. (AIMD) filed an 8-K detailing shareholder voting results and the furnishing of a press release with results for the quarter ended September 30, 2025.
At the November 7 Annual Meeting, a quorum was present with 3,226,793 votes, representing approximately 67.63% of outstanding votes. Seven directors were elected with vote support near or above 98%. Shareholders approved the ratification of YCM CPA INC. as independent auditor for the fiscal year ending December 31, 2025.
Shareholders also approved the reservation of up to 950,000 shares of common stock as special stock awards not issued under the 2023 Stock Incentive Plan. As of the September 17 record date, 4,771,184 common shares were outstanding and entitled to vote. The company furnished, but did not file, a press release announcing quarterly results as Exhibit 99.1.
Ainos, Inc. entered a Fourth Addendum to its Product Development Agreement with Taiwan Carbon Nano Technology Corporation (TCNT). The amendment sets a fee for the exclusive use of patents of $50,000 per month plus 5% sales tax for a two-year period starting October 16, 2025, replacing the prior one-year period starting October 16, 2024.
TCNT controls the company through its majority interest in Ainos KY and direct ownership, with Ainos KY holding majority voting power via voting agreements. The parties may negotiate payment terms and subsequent licensing methods after the two-year period. An English translation of the Fourth Addendum is filed as Exhibit 10.1.
Taiwan Carbon Nano Technology Corporation (TCNT) reports it directly holds 1,037,206 shares of Ainos, Inc. common stock, representing 21.79% of the outstanding shares after the issuer's one-for-five reverse stock split. TCNT acquired a larger position when the issuer issued 5,500,000 shares under a license agreement in exchange for patent rights and subsequently adjusted for the reverse split.
TCNT sold 62,794 shares between the end of June and early October and states those sales were for general operating purposes. TCNT is subject to a voting agreement that requires it to vote its shares as directed by Ainos KY while Ainos KY holds at least 10% of the issuer's shares. No litigation or other arrangements are disclosed.
Ainos Inc. amended its Schedule 13D to report ownership and recent transactions involving the issuer's common stock. After a
The filing states the direct holdings of
Form 4 disclosure: Taiwan Carbon Nano Technology Corporation, reported by Chun-Hsien Tsai as reporting person, recorded an insider sale in Ainos, Inc. (AIMD). On
Ainos, Inc. (AIMD) reported a Form 4 showing that Taiwan Carbon Nano Technology Corporation, a director-related reporting person, sold 2,000 shares of common stock on
Taiwan Carbon Nano Technology Corporation, identified as a director of Ainos, Inc. (AIMD), reported two open-market stock sales. On 09/30/2025 the reporting person sold 1,006 shares at $3.5167 each, reducing beneficial holdings to 1,047,906 shares. On 10/01/2025 they sold 1,700 shares at $3.4633, reducing holdings to 1,046,206 shares. The filing states the shares were sold for general operating purposes. The transactions are reported as direct beneficial ownership and coded as sales.
Ainos, Inc. provides details in its definitive proxy about ownership, director compensation and executive pay adjustments. Two large shareholders are disclosed: Taiwan Carbon Nano Technology Corporation holds 5,500,000 shares (35.64%) and ASE Test, Inc. holds 2,312,077 shares (13.05%). The document discloses board compensation rates including an annual chair retainer of $14,000, audit chair $7,000, compensation chair $4,500, audit committee members $4,000, and compensation committee members $3,000. Director ages are listed (examples: Wen-Han Chang 62; Yao-Chung Chiang 73; Pao-Sheng Wei 67). Chun-Hsien Tsai served as CEO and received a 2023 base salary of $122,517, bonus $115,313 and stock awards valued at $63,692. The proxy includes adjustments used to calculate "compensation actually paid" and reports total compensation actually paid figures (examples: $209,991, $440,794, $223,625, $551,615). The board will solicit proxies to ratify YCM as the independent registered public accounting firm for fiscal 2024 and to authorize adjournment of the annual meeting.
FAQ
What is the current stock price of Ainos (AIMD)?
What is the market cap of Ainos (AIMD)?
